Double-edged sword: a p53 regulator mediates both harmful and beneficial effects in experimental acute kidney injury  by McNicholas, Bairbre A. & Griffin, Matthew D.
commentar y
Kidney International (2012) 81     1161
 Th ere continues to be intense interest in 
furthering our understanding of the cel-
lular and molecular mechanisms underly-
ing acute kidney injury (AKI) through the 
consult. Studies were heterogeneous with 
regard to the predefi ned use of appropriate 
nephrology consultation indications; one 
study used discharge from nephrology 
care within one year of consultation as 
the defi nition of an inappropriate use of 
resources. 7 Two studies evaluated changes 
in the timing of referral relative 
to the onset of chronic kidney failure 
following reporting, but the use of signi-
ficantly different definitions of early 
and late consultation complicated the 
assessment. 7 
 Assessment of the future impact of 
eGFR reporting 
 Th ese preliminary studies are encouraging 
in the overall trend for a benefi t of eGFR 
reporting. Data are needed on the impact 
of reporting on patient and public aware-
ness of CKD and its risk factors and out-
comes. 10 Evaluation of the impact of 
reporting will be essential for the refi ne-
ment of methods of estimating GFR, such 
as the CKD Epidemiology Collaboration 
(CKD-EPI) 2009 creatinine equation and 
the 2012 CKD-EPI cystatin C equation. It 
will also be important to investigate patient 
safety, but the metrics will need to be more 
precisely defi ned. What is the impact of 
eGFR reporting on the timing of dialysis 
initiation? Will there be an infl uence of 
reporting when enough time has elapsed 
to accrue adequate hard end points for car-
diovascular events, onset of chronic kidney 
failure, and mortality? Future studies of 
eGFR reporting should further explore the 
impact of the prompt as a form of clinical 
decision support. Th ere is advance notice 
to consider the implementation before 
publication of an updated CKD CPG 
anticipated in 2012 from Kidney Disease: 
Improving Global Outcomes and the cor-
responding K / DOQI US Commentary. 
Th is will provide an opportunity to reframe 
the discussion regarding the controver sies 
and adoption challenges for routine pri-
mary and nephrology CKD care in a 
second cycle of development, publication, 
and implementation. 
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 Double-edged sword: a p53 
regulator mediates both 
harmful and beneficial effects in 
experimental acute kidney injury 
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 Acute kidney injury triggers activation of innate immune responses and 
of proapoptotic programs such as the p53 pathway. Mulay  et al. examine 
the effects of blocking murine double minute-2 (mdm2), a negative 
regulator of p53, using a novel chemotherapeutic agent, nutlin-3a, in 
mouse ischemia – reperfusion injury. Their results indicate that mdm2 
promotes renal regeneration by limiting p53-mediated apoptosis but 
also enhances early inflammation by facilitating DNA binding of nuclear 
factor-  B independently of p53. 
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use of animal models. 1 Although attempts 
at translation of laboratory research fi nd-
ings to patient populations with AKI have 
yet to yield dramatic clinical benefits, 
there is now a clearer appreciation of the 
complexity of this challenge. 1 Th ere is also 
an emerging consensus that robust pre-
ventative or therapeutic interventions may 
require the manipulation of multiple path-
ways to renal injury — either simultane-
ously or at diff erent stages of the process. 1 
Two mechanisms of injury that may be of 
specific interest in this regard are the 
see original article on page 1199
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intense immune / infl ammatory response 
that is initiated early in the course of 
diverse forms of AKI and the activation of 
intracellular pathways associated with 
apoptotic cell death. 1,2 A corollary to this 
point is that the failure of some individual 
therapies to translate into improved AKI 
outcomes in human clinical trials may be 
due to opposing benefi cial and detrimen-
tal eff ects on diff erent components of the 
injury response. Finally, while it is clear 
that the various common causes of AKI 
trigger an overlapping set of tissue 
response programs, 1 some forms of renal 
damage, such as cancer chemotherapy-
associated nephrotoxicity, 3 may be associ-
ated with discrete primary mechanisms 
that will allow tailored therapies or pre-
ventative measures to be developed. 
 Mulay  et al. 4 (this issue) provide novel 
insights into AKI pathogenesis that strik-
ingly underscore both the value of animal 
model experimentation in this fi eld and 
the complexity of applying such insights 
to the clinical setting. Th e study, from the 
laboratory of Hans-Joachim Anders, 
examines the role of murine double 
minute-2 (mdm2) — an E3 ubiquitin ligase 
known to negatively regulate the proap-
optotic transcription factor p53 5 — in 
mouse ischemia – reperfusion injury (IRI). 
An important rationale for the study was 
the recent development of mdm2 inhibi-
tors such as nutlin-3a for clinical use 
as anticancer agents based on their ability 
to enhance p53-driven upregulation of 
proapoptotic gene products in neoplastic 
cells. 6 Given that expression of p53 
is known to be increased in renal paren-
chymal cells during AKI and to have 
a detrimental impact on renal tubular 
regeneration, 7,8 the authors logically 
hypothesized that stabilization and activa-
tion of p53 by nutlin-3a would exacerbate 
AKI by exaggerating the apoptotic 
response in renal parenchymal cells 
( Figure 1a and b ). In keeping with this, 
they observed that nutlin-3a further 
increased total and phosphorylated p53 
levels aft er IRI with resultant increases 
in intrarenal transcript levels of p53-
dependent proapoptotic proteins such as 
BAD, BID, and NOXA. Furthermore, 
blood urea nitrogen and tubular injury 
scores were increased and proximal and 
distal tubular cell viability was decreased 
during the  ‘ regeneration phase ’ (5 days 
post-IRI) in nutlin-3a-treated animals — 
an eff ect that was absent in p53-defi cient 
mice. Th ese fi ndings support the concern 
that patients receiving nutlin-3a therapy 
may experience heightened susceptibility 
to acute renal failure following nephro-
toxic insults as a direct result of increased 
p53 activation. Th ey are also consistent 
with the fi ndings of Molitoris  et al. , who 
performed  in vivo siRNA knockdown 
of p53 in the kidney following IRI and 
cisplatin nephrotoxicity and observed 
dose-dependent improvements in post-
AKI renal function, cortical and medul-
lary tubular necrosis, and number of 
apoptotic cells. 8 
 However, the p53-dependent disruption 
of tubular regeneration was not the only 
effect of mdm2 blockade observed by 
Mulay  et al. following IRI. 4 Nutlin-3a 
administration was also associated with a 
striking reduction in early loss of renal 
function and with reduced intrarenal 
infl ammation. In contrast to the day 5 
results, at 24  h aft er renal artery clamping, 
animals receiving nutlin-3a had lower 
serum creatinine and blood urea nitrogen 
concentrations compared with vehicle-
treated controls. At this same time point, 
their kidneys exhibited reduced tubular 
injury and apoptotic cell numbers, 
increased proximal and distal tubular 
epithelial cell viability, reduced neutrophil 
infi ltration, and reduced mRNA levels of 
the proinfl ammatory mediators tumor 
necrosis factor (TNF), CXCL2, CCL2, and 
interleukin-6. Interestingly, the increased 
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 Figure 1  |  Dual effects of murine double minute-2 blockade during acute kidney injury based 
on the results of Mulay  et al. 4 ( a ) In its best-described role, murine double minute-2 (mdm2) 
interacts with p53 via an N-terminal domain and targets p53 for nuclear export or, by E3 ubiquitin 
ligase activity, for proteosomal degradation. During acute kidney injury (AKI), this function of 
mdm2 may limit p53-mediated upregulation of proapoptotic genes and, by so doing, promote 
tubular epithelial cell survival and proliferation during the regenerative phase. ( b ) In the presence 
of the mdm2 blocker nutlin-3a (n3a), p53-mediated transcription of proapoptotic gene products 
such as BAD, BID, and NOXA is enhanced, favoring increased epithelial cell apoptosis and inferior 
recovery of kidney function. ( c ) In cells of the innate immune system such as intrarenal dendritic 
cells, mdm2 may facilitate binding of the transcription nuclear factor-  B (NF-  B) to promoter 
regions of genes encoding proinflammatory mediators such as tumor necrosis factor (TNF), 
CXCL2, and CCL2 in response to Toll-like receptor (TLR) signaling initiated by release of 
danger-associated molecular patterns (DAMPs). This property of mdm2 promotes a potent 
inflammatory response that may exacerbate early tissue damage and cell loss during AKI. 
( d ) For this mechanism of action of mdm2, the inhibitor nutlin-3a is associated with attenuated 
NF-  B-driven transcription of proinflammatory genes, resulting in a restrained inflammatory 
response and reduced early tissue injury and loss of kidney function. 
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intrarenal expression of mRNA for TNF, 
CXCL2, and CCL2 that occurred at 
24 hours aft er IRI was localized by cell 
separation to CD11c   +   dendritic cells and 
was specifi cally diminished in these cells 
in nutlin-3a-treated animals. These 
un anticipated results imply that mdm2 
functions in some fashion as a positive 
regulator of the proinfl ammatory response 
to tissue injury — perhaps specifi cally in 
tissue resident mononuclear phagocytes 
such as renal dendritic cells ( Figure 1c 
and d ). Th ey also indicate a potential for 
the use of mdm2 inhibitors in immune / 
inflammatory diseases — a possibility 
that is strengthened by the same group ’ s 
recent report of beneficial effects of 
nutlin-3a on autoimmune tissue injury in 
the MRL-Fas  lpr  model of systemic lupus 
erythematosis. 9 
 Th e observed anti-infl ammatory eff ects 
of nutlin-3a in both AKI and lupus 
models evoke important questions about 
the mechanism whereby mdm2 enhances 
immune / infl ammatory responses and the 
potential for this mechanism to be sepa-
rated, for therapeutic purposes, from its 
role in preventing p53-mediated apopto-
sis. It is worth, therefore, considering the 
molecular interactions and functions of 
mdm2 in more detail. In its best-charac-
terized role, mdm2 inhibits transactiva-
tion of p53, exports p53 out of the nucleus, 
and promotes proteosomal degradation of 
p53 through its E3 ubiquitin ligase activity 
( Figure 1a ). 5,6 Th e p53 – mdm2 interaction 
occurs between the N-terminal domains 
of both proteins. Th is interaction is dis-
rupted by nutlin-3a, leading to accumula-
tion and activation of p53, which controls 
the cellular response to endogenous injury 
by upregulating expression of cell-cycle, 
apoptotic, DNA repair and senescence 
genes that determine cell fate ( Figure 1b ). 6 
In addition, however, mdm2 has been 
reported to regulate the expression and / or 
degradation of a range of target proteins 
independently of its interaction with 
p53. Such targets include the retinoblas-
toma susceptibility gene product pRB, the 
trans cription factors E2F1 and Foxo3A, 
the antiapoptotic protein XIAP, and 
E-cadherin. 5 Some of these interactions 
clearly involve domains of the mdm2 pro-
tein that are distinct from the p53-binding 
N-terminus. 5 It has also been noted, how-
ever, that high doses of nutlins affect 
proliferation of tumor cells that lack p53, 
indicating that modulation of mdm2 at its 
p53-binding site aff ects its activity on tar-
gets independent of p53. 6 
 To begin to elucidate the mechanism of 
reduced early infl ammation in their IRI 
experiments, Mulay  et al. have conducted 
a careful series of experiments, focusing 
primarily on nuclear factor-  B (NF-  B)-
mediated upregulation of proinfl ammatory 
mediators. 4 Lipopolysaccharide (LPS) 
stimulation of p53-deficient and p53 /
 mdm2-double-defi cient mouse embryonic 
fi broblasts was used to determine whether 
p53 was necessary for mdm2-dependent 
induction of interleukin-6 and TNF. Inter-
estingly, while LPS-induced secretion of 
IL-6 and TNF occurred robustly in p53-
defi cient cells, combined defi ciency of p53 
and mdm2 resulted in the virtual absence 
of cytokine production. Despite this strik-
ing diff erence, proximal signaling events 
associated with LPS stimulation were intact 
in the double-deficient cells, including 
phosphorylation and degradation of I  B, 
nuclear translocation of the NF-  B pro-
teins p65 and p52, and activation of 
mitogen-activated protein kinase signaling 
pathways. In contrast, it was found that 
LPS-induced recruitment of NF-  B to the 
 il-6 gene promoter and transcriptional 
activity from an  il-6 promoter-driven 
reporter construct were reduced in the 
combined absence of p53 and mdm2. On 
this basis, the authors conclude that the 
proinfl ammatory function of mdm2 inhi-
bition is (1) independent of p53 and (2) the 
result of an intranuclear mechanism 
whereby mdm2 facilitates binding of 
NF-  B dimers to promoter regions of key 
target genes ( Figure 1c ). Whether this 
mechanism of action refl ects direct inter-
action between mdm2 and NF-  B proteins 
in the nucleus or is mediated indirectly by 
an eff ect of mdm2 on the accessibility of 
promoter DNA via, for instance, histone-
modifying enzyme systems 10 will require 
further study. It should also be noted that 
additional mechanisms for mdm2-
mediated enhancement of NF-  B-driven 
infl ammatory gene transcription have been 
reported. For example, in a model of LPS-
induced acute lung injury, treatment of 
mice with nutlin-3a resulted in reduced 
severity of lung injury and its associated 
infl ammatory components. In the same 
study, culture of neutrophils and macro-
phages with nutlin-3a decreased LPS-
induced NF-  B-binding activity, but this 
eff ect was dependent on the presence of 
p53. 11 Given the complexity of the molec-
ular interactions of both mdm2 and p53 
as well as the diversity of their potential 
eff ects on protein stability, intracellular 
signaling events, and gene transcription, 5,6 
it is possible that the anti-infl ammatory 
eff ects of mdm2 inhibition involve multi-
ple mechanisms that differ by cell type 
and context. 
 Th e results reported by Mulay  et al. in 
this comprehensive study 4 are compelling 
for both the clinical nephrologist and the 
renal physiologist. Although the potential 
detrimental eff ect of the novel chemo-
therapeutic agent nutlin-3a on renal 
regeneration following AKI is demon-
strated, we have also learned that mdm2 
inhibition holds real promise as a strategy 
to reduce tissue damage associated with 
renal infl ammation. 4,9 Th e fi ndings pro-
vide a strong impetus for additional bio-
chemical and  in vivo experiments aimed 
at more precisely defi ning the molecular 
details of mdm2-mediated enhancement 
of proinfl ammatory mediator expression, 
particularly in immunological cells such 
as renal dendritic cells. The clinician 
may also note that the law of unintended 
consequences, so frequently encountered 
during the management of patients 
with renal failure, is well illustrated here: 
what may appear to be a useful outcome 
in the early stages of an illness (decreased 
immune system activation) can prove 
to be disappointing in the long term 
(impaired regeneration as a result of 
increased cellular senescence and apop-
tosis). The study of Mulay  et al. 4 does, 
however, provide reason to believe that 
continued progress in understanding the 
molecular pathways linking immune / 
infl ammatory response with epithelial cell 
apoptosis and regeneration throughout 
the course of AKI will serve as a basis for 
more successful therapeutic strategies in 
the future. 
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 Th e risk of cardiovascular disease is high 
in patients with chronic kidney disease, 
and cardiovascular disease accounts for up 
to 50 % of deaths in this population. In the 
subset of patients receiving hemodialysis 
the rate of cardiovascular mortality is 10 – to 
20 – fold higher than that of the general 
population. 1 In addition to a high preva-
lence of traditional cardiovascular risk 
factors in patients with chronic renal 
disease (for example, hypertension and 
diabetes mellitus), other specific risk 
factors, including degree of uremia, 
comorbidity, inflammatory response, 
hypoalbuminemia, and hyperparathy-
roidism, also seem to contribute to the 
excess cardiovascular risk. 
 Th e antiphospholipid syndrome (APS) 
is an acquired, strongly prothrombotic 
disease characterized by arterial and ven-
ous thromboembolism and / or pregnancy 
morbidity in the presence of persistent 
high-titer autoantibodies directed against 
a broad range of phospholipids and phos-
pholipid-binding proteins. 2 Th e history of 
APS dates back to reports in the 1950  s 
of false-positive laboratory test results 
for syphilis in patients who went on 
to develop systemic lupus erythema tosus 
(SLE). It became apparent that Wasserman 
 et al. had detected the earliest anti-phos-
pholipid antibodies in 1906 with the 
development of a complement-fi xation 
assay for syphilis using phospholipid anti-
gen from hepatic extract of fetuses with 
congenital syphilis. 3 Th is phospho lipid 
antigen was later named  ‘ cardiolipin ’ (as 
subsequently mitochondrial phospholip-
ids were extracted from bovine heart mus-
cle), and anti-cardiolipin antibody 
detection became the basis of the current-
day Venereal Disease Research Laboratory 
(VDRL) test for syphilis. Widespread 
screening of donated blood for syphilis led 
to the realization that some patients with 
SLE possessed anti-phospholipid antibod-
ies resulting in false-positive VDRL tests, 
prolonged laboratory clotting times, and 
strong predisposition to thrombosis. 
 Anti-phospholipid antibodies are 
detected either by a prolongation of phos-
pholipid-dependent coagulation tests 
(lupus anticoagulant) or by solid-phase 
immune assays. Th ey are a heterogeneous 
group of autoantibodies directed against 
a variety of diff erent antigens (including 
prothrombin, annexin V, protein C, and 
protein S); it is thought that binding of 
these antigens is at least partly responsible 
for the prothrombotic phenotype of APS. 
In the early 1990s, several groups reported 
that a proportion of anti-cardiolipin anti-
bodies were directed against the phos-
pholipid cofactor   2 glycoprotein I 
(  2GPI). Th is single-chain polypeptide 
glycoprotein is a 50 – kDa plasma apolipo-
protein (plasma concentration 200   g / ml) 
that binds anionic phospholipids; it is 
required for anti-phospholipid antibody 
binding in a subset of patients with SLE 
 Does IgA antibody against 
  2 glycoprotein I increase 
cardiovascular risk in 
hemodialysis patients ? 
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 Cardiovascular disease is the most common cause of mortality in 
patients with chronic kidney disease on hemodialysis. In addition to a 
high prevalence of traditional cardiovascular risk factors, other specific 
factors, including uremia and chronic inflammation, seem to contribute 
to the excess cardiovascular mortality. The findings of Serrano  et al. 
point to a link between IgA antibodies against   2 glycoprotein I 
and cardiovascular events in renal dialysis patients. 
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